SCHEMBL12828541

SCHEMBL12828541

CC(C)COCCN(C(=O)Nc1ncc(SCC(=O)O)s1)C1CCCCC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 17/20 0.38
CCNE2 O96020 15/20 0.38
CCNE1 P24864 15/20 0.38
CCNB2 O95067 8/20 0.38
CDK1 P06493 8/20 0.38
CDK4 P11802 8/20 0.38
CCNB1 P14635 8/20 0.38
CCND1 P24385 8/20 0.38
CCNB3 Q8WWL7 8/20 0.38
ADORA2A P29274 1/20 0.34
ADORA1 P30542 1/20 0.34
CDK9 P50750 4/20 0.34
CIT O14578 1/20 0.33
CASK O14936 1/20 0.33
AURKA O14965 1/20 0.33
GAK O14976 1/20 0.33
DCLK1 O15075 1/20 0.33
MAP3K7 O43318 1/20 0.33
CCNT1 O60563 1/20 0.33
ULK1 O75385 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1240518 0.92 CDK2 (0.37) CDK2CCNE2CCNE1CCNB2CDK1
SCHEMBL12828543 0.91 CDK2 (0.39) CDK2CCNE2CCNE1CCNB2CDK1
SCHEMBL12828939 0.90 CDK2 (0.44) CDK2CCNE2CCNE1CCNB2CDK1
SCHEMBL12828686 0.89 CCNE2 (0.39) CDK2CCNE2CCNE1CCNB2CDK1
SCHEMBL1241652 0.88 CCNE2 (0.40) CDK2CCNE2CCNE1CCNB2CDK1
SCHEMBL12828940 0.87 CDK2 (0.39) CDK2CCNE2CCNE1CCNB2CDK1
SCHEMBL12828451 0.86 CCNE1 (0.43) CDK2CCNE2CCNE1CCNB2CDK1
SCHEMBL12828219 0.86 CDK2 (0.50) CDK2CCNE2CCNE1CCNB2CDK1
SCHEMBL12828220 0.85 CCNE1 (0.38) CDK2CCNE2CCNE1CCNB2CDK1
SCHEMBL12204125 0.85 CCNE1 (0.48) CDK2CCNE2CCNE1CCNB2CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110077234-A1 Urea Glucokinase Activators NOVO NORDISK A/S (DK) 2011-03-31 US disclosed
US-7884210-B2 {2-[3-(2-Cyclohex-1-enyl-ethyl)-3-(trans-4-methyl-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid; for treatment of type 2 diabetes NOVO NORDISK A/S (DK) 2011-02-08 US disclosed
US-20090105482-A1 Urea Glucokinase Activators NOVO NORDISK A/S (DK) 2009-04-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105482-A1 Urea Glucokinase Activators GCK, GCKR, HK2 CDK2 268/4885CCNE2 1371/4885CCNE1 2561/4885
US-20110077234-A1 Urea Glucokinase Activators GCK, GCKR, HK2 CDK2 268/4885CCNE2 1371/4885CCNE1 2561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.